Fig. 1



CloneR82-1
WT1-332
Solvent
HEV#0052
HEV#0324
HEV#0042
HEV#0238
HEV#0013
HEV#0057
Antigen Presenting Cells
0
5000
10000
15000
20000
25000
30000
IFN-γ (pg/mL)

Fig. 2



CloneR132-1
WT1-332
Solvent
HEV#0201
HEV#0073
HEV#0271
1333-8272
HEV#0046
HEV#0038
HEV#0110
HEV#0024
HEV#0342
Antigen Presenting Cells
0
20000
40000
60000
80000
IFN-γ (pg/mL)

Fig. 3



CloneR143-1
WT1-332
Solvent
HEV#0052
HEV#0324
HEV#0042
HEV#0238
HEV#0035
HEV#0012
HEV#0057
HEV#0013
HEV#0342
HEV#0050
Antigen Presenting Cells
0
5000
10000
15000
20000
25000
30000
IFN-γ (pg/mL)

Fig. 4



CloneR145-2
WT1-332
Solvent
HEV#0201
HEV#0073
ISH5
HEV#0271
HEV#0058
HEV#0055
HEV#0035
HEV#0050
Antigen Presenting Cells
0
5000
10000
15000
IFN-γ (pg/mL)

Fig. 5




CloneQ32-1
WT1-332
Solvent
Antigen Presenting Cells
HEV#0052
HEV#0324
HEV#0238
HEV#0042
HEV#0013
0
2000
4000
6000
8000
10000
IFN-γ (pg/mL)

Fig. 6


CloneQ41-1
WT1-332
Solvent
HEV#0201
HEV#0073
HEV#0174
HEV#0013
HEV#0035
HEV#0050
Antigen Presenting Cells
0
10000
20000
30000
40000
50000
IFN-γ (pg/mL)

SEQUENCE LISTING

<110> Otsuka Pharmaceutical Co., Ltd.
Osaka University

<120> Method for activating helper T cell

<130> 671805

<150> JP 2012-274494
<151> 2012-12-17

<160> 2

<170> PatentIn version 3.2

<210> 1
<211> 449
<212> PRT
<213> Homo sapiens

<400> 1

```
Met Gly Ser Asp Val Arg Asp Leu Asn Ala Leu Leu Pro Ala Val Pro
 1               5                  10                  15

Ser Leu Gly Gly Gly Gly Gly Cys Ala Leu Pro Val Ser Gly Ala Ala
            20                  25                  30

Gln Trp Ala Pro Val Leu Asp Phe Ala Pro Pro Gly Ala Ser Ala Tyr
        35                  40                  45

Gly Ser Leu Gly Gly Pro Ala Pro Pro Pro Ala Pro Pro Pro Pro Pro
    50                  55                  60

Pro Pro Pro Pro His Ser Phe Ile Lys Gln Glu Pro Ser Trp Gly Gly
65                  70                  75                  80

Ala Glu Pro His Glu Glu Gln Cys Leu Ser Ala Phe Thr Val His Phe
                85                  90                  95

Ser Gly Gln Phe Thr Gly Thr Ala Gly Ala Cys Arg Tyr Gly Pro Phe
            100                 105                 110

Gly Pro Pro Pro Pro Ser Gln Ala Ser Ser Gly Gln Ala Arg Met Phe
        115                 120                 125

Pro Asn Ala Pro Tyr Leu Pro Ser Cys Leu Glu Ser Gln Pro Ala Ile
    130                 135                 140

Arg Asn Gln Gly Tyr Ser Thr Val Thr Phe Asp Gly Thr Pro Ser Tyr
145                 150                 155                 160

Gly His Thr Pro Ser His His Ala Ala Gln Phe Pro Asn His Ser Phe
                165                 170                 175

Lys His Glu Asp Pro Met Gly Gln Gln Gly Ser Leu Gly Glu Gln Gln
            180                 185                 190

Tyr Ser Val Pro Pro Pro Val Tyr Gly Cys His Thr Pro Thr Asp Ser
        195                 200                 205

Cys Thr Gly Ser Gln Ala Leu Leu Leu Arg Thr Pro Tyr Ser Ser Asp
    210                 215                 220

Asn Leu Tyr Gln Met Thr Ser Gln Leu Glu Cys Met Thr Trp Asn Gln
225                 230                 235                 240
```

```
Met Asn Leu Gly Ala Thr Leu Lys Gly Val Ala Ala Gly Ser Ser Ser
245                 250                 255

Ser Val Lys Trp Thr Glu Gly Gln Ser Asn His Ser Thr Gly Tyr Glu
            260                 265                 270

Ser Asp Asn His Thr Thr Pro Ile Leu Cys Gly Ala Gln Tyr Arg Ile
        275                 280                 285

His Thr His Gly Val Phe Arg Gly Ile Gln Asp Val Arg Arg Val Pro
    290                 295                 300

Gly Val Ala Pro Thr Leu Val Arg Ser Ala Ser Glu Thr Ser Glu Lys
305                 310                 315                 320

Arg Pro Phe Met Cys Ala Tyr Pro Gly Cys Asn Lys Arg Tyr Phe Lys
                325                 330                 335

Leu Ser His Leu Gln Met His Ser Arg Lys His Thr Gly Glu Lys Pro
            340                 345                 350

Tyr Gln Cys Asp Phe Lys Asp Cys Glu Arg Arg Phe Ser Arg Ser Asp
        355                 360                 365

Gln Leu Lys Arg His Gln Arg Arg His Thr Gly Val Lys Pro Phe Gln
    370                 375                 380

Cys Lys Thr Cys Gln Arg Lys Phe Ser Arg Ser Asp His Leu Lys Thr
385                 390                 395                 400

His Thr Arg Thr His Thr Gly Lys Thr Ser Glu Lys Pro Phe Ser Cys
                405                 410                 415

Arg Trp Pro Ser Cys Gln Lys Lys Phe Ala Arg Ser Asp Glu Leu Val
            420                 425                 430

Arg His His Asn Met His Gln Arg Asn Met Thr Lys Leu Gln Leu Ala
        435                 440                 445

Leu
```

<210> 2
<211> 16
<212> PRT
<213> Artificial

<220>
<223> Synthetic peptide

<400> 2

```
Lys Arg Tyr Phe Lys Leu Ser His Leu Gln Met His Ser Arg Lys His
 1               5                  10                  15
```